Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

There is no fulltext present in this item.

Title:	Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine
Author(s):	Theisen, M.; Jore, M.M.; Sauerwein, R.
Publication year:	2017
Source:	Expert Review of Vaccines, vol. 16, iss. 4, (2017), pp. 329-336
ISSN:	1476-0584
DOI:	https://doi.org/10.1080/14760584.2017.1276833
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/170299
Display more details
Subject:	Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Medical Microbiology
Journal title:	Expert Review of Vaccines
Volume:	vol. 16
Issue:	iss. 4
Page start:	p. 329
Page end:	p. 336
Abstract:	INTRODUCTION: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.